| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Jerel Davis | Director | C/O TURNSTONE BIOLOGICS CORP., 1110 NORTH VIRGIL AVENUE PMB 94659, LOS ANGELES | /s/ Jerel Davis | 2024-08-08 | 0001745958 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TSBX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -275K | -100% | 0 | Aug 8, 2025 | By Versant Vantage II, L.P. | F1, F2 | ||
| transaction | TSBX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -2.73M | -100% | 0 | Aug 8, 2025 | By Versant Venture Capital V, L.P. | F1, F3 | ||
| transaction | TSBX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -207K | -100% | 0 | Aug 8, 2025 | By Versant Venture Capital V (Canada) LP | F1, F4 | ||
| transaction | TSBX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -90.9K | -100% | 0 | Aug 8, 2025 | By Versant Ophthalmic Affiliates Fund I, L.P. | F1, F5 | ||
| transaction | TSBX | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -82K | -100% | 0 | Aug 8, 2025 | By Versant Affiliates Fund V, L.P. | F1, F6 |
| Id | Content |
|---|---|
| F1 | Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. |
| F2 | Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| F3 | Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. |
| F4 | Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| F5 | Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. |
| F6 | Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. |